
Darovasertib Plus Crizotinib Yields 21.1-Month OS in First-Line Uveal Melanoma
In OptimUM-01, darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in untreated metastatic uveal melanoma, regardless of HLA status.
Combining darovasertib with crizotinib (Xalkori) produced positive efficacy with a manageable safety profile among patients with previously untreated metastatic uveal melanoma, according to phase 2 findings from the OptimUM-01 study (NCT03947385) published in the Journal of Clinical Oncology.1
Efficacy Results of OptimUM-01 Trial
Among 44 treatment-naïve patients, the median overall survival (OS) was 21.1 months (95% CI, 12.5-27.1), and the median progression-free survival (PFS) was 7.0 months (95% CI, 3.8-7.7) at a median study follow-up of 25 months. The 6- and 12-month PFS rates were 52% and 28%, respectively.
In the efficacy-evaluable population (n = 41), the confirmed objective response rate (ORR) was 34.1% (95% CI, 20.1%-50.6%), with all responses being partial responses. An additional 56.1% of patients achieved stable disease, and 9.8% had progressive disease. The median duration of response (DOR) was 9.0 months (95% CI, 3.8-12.0), and the median time to response was 2.0 months. The disease control rate (DCR) was 90.2% (95% CI, 76.9%-97.3%) at 8 weeks and 53.7% (95% CI, 37.4%-69.3%) at 26 weeks.
Antitumor activity was observed irrespective of human leukocyte antigen (HLA) status. Among patients who were HLA-A*02:01–positive (n = 10), the ORR was 30.0% with a median DOR of 10.15 months; among those who were HLA-A*02:01–negative (n = 29), the ORR was 31.0% with a median DOR of 9.03 months. Responses were also seen across lactate dehydrogenase (LDH) subgroups, including an ORR of 66.7% (95% CI, 22.3%-95.7%) among the 6 evaluable patients with LDH levels more than 2 times the upper limit of normal (ULN).
Molecular responses supported these findings. Among 20 patients with GNAQ/11 mutations identified in tumor tissue, all had detectable circulating cell-free DNA (cfDNA) at baseline, and 95% (19/20) achieved a molecular response, defined as a reduction in cfDNA of more than 50% from baseline. These responses occurred regardless of metastatic site.
OptimUM-01 Trial Design
OptimUM-01 was a phase 1/2, multicenter, open-label, dose-escalation and expansion study. The current analysis focused on the phase 2 expansion cohort of patients with no prior therapy for metastatic disease, who received darovasertib at 300 mg twice daily plus crizotinib at 200 mg twice daily. The first cycle included a 7-day darovasertib run-in, followed by continuous combination dosing in 28-day cycles, with tumor assessments every 8 weeks. Eligible patients were required to have measurable disease per RECIST v1.1, an ECOG performance status of 0 or 1, and adequate organ function. End points included safety, ORR, DOR, DCR, PFS, and OS.
The median patient age was 64.5 years (range, 21-80), and many patients had high-risk features: 43.2% had a metastatic lesion greater than 3 cm, 31.8% had elevated baseline LDH, and 40.9% had both hepatic and extrahepatic disease. Overall, 27.3% of patients were HLA-A*02:01–positive and 68.2% were HLA-A*02:01–negative.
Safety Results of Darovasertib Plus Crizotinib
Regarding safety, all patients experienced at least 1 treatment-emergent adverse event (TEAE), and 52.3% experienced a grade 3 or higher TEAE. The most common TEAEs were diarrhea (95.5%), nausea (84.1%), peripheral edema (61.4%), and vomiting (52.3%). The most common grade 3 or higher events were pulmonary embolism (9.1%) and iron deficiency anemia (6.8%). Serious TEAEs occurred in 20.5% of patients.
TEAEs led to discontinuation in 3 patients (6.8%). Adverse events related to darovasertib and crizotinib led to dose reductions in 6.8% and 9.1% of patients, respectively, and 68.2% of patients had at least 1 dose hold. Mean cumulative dose intensity was 84.9% for darovasertib and 80.0% for crizotinib. Two patients experienced grade 5 events; one was deemed unrelated to treatment, and the other was considered possibly related but more likely the result of multiple factors associated with advanced disease. Hypotension, previously the most common dose-limiting toxicity of darovasertib, occurred in 8 patients; most events were grade 1 or 2, occurred early in treatment, and resolved quickly, with no discontinuations due to hypotension. No new safety signals were identified.
The investigators acknowledged that cross-trial comparisons carry limitations but noted that the median PFS compared favorably with a historical benchmark of approximately 2.8 months from a meta-analysis of prior trials, and that the median OS was longer than the 10 to 12 months typically seen with standard first-line approaches. Because OptimUM-01 was an open-label, single-arm study, the authors described the results as hypothesis-generating and noted that PFS and OS data will continue to mature.
Next Steps for the Combination
The combination is under further evaluation in the randomized phase 2/3 OptimUM-02 trial (NCT05987332), which compares darovasertib plus crizotinib with investigator’s choice of pembrolizumab (Keytruda), nivolumab (Opdivo) plus ipilimumab (Yervoy), or dacarbazine in the first-line setting. According to the authors, the trial has completed enrollment and has reported positive top-line results. Darovasertib is also being evaluated as neoadjuvant monotherapy in primary uveal melanoma in the OptimUM-10 study (NCT07015190), and an adjuvant trial of the combination is being planned.
Reference
McKean M, Chmielowski B, Butler MO, et al. Darovasertib and crizotinib first-line treatment for metastatic uveal melanoma: overall survival, efficacy, and safety from the OptimUM-01 study. J Clin Oncol. Published online October 28, 2026. doi:10.1200/JCO-26-00802
Related to this article








